(VIANEWS) – The NASDAQ opens in less than hour and Hologic‘s pre-market value is already 4.64% down.
Hologic’s last close was $77.96, 11.29% under its 52-week high of $87.88.
The last session, NASDAQ finished with Hologic (HOLX) rising 0.79% to $77.96. NASDAQ fell 0.12% to $16,379.46, following the last session’s downward trend on what was a somewhat negative trend trading session.
About Hologic
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and connectivity solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, the company offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
Earnings Per Share
As for profitability, Hologic has a trailing twelve months EPS of $2.11.
PE Ratio
Hologic has a trailing twelve months price to earnings ratio of 36.95. Meaning, the purchaser of the share is investing $36.95 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.57%.
Yearly Top and Bottom Value
Hologic’s stock is valued at $77.96 at 10:04 EST, way under its 52-week high of $87.88 and way above its 52-week low of $64.02.
Moving Average
Hologic’s worth is higher than its 50-day moving average of $73.73 and above its 200-day moving average of $73.87.
More news about Hologic (HOLX).
